| Followers | 28 |
| Posts | 5021 |
| Boards Moderated | 0 |
| Alias Born | 09/22/2006 |
Sunday, July 28, 2024 9:04:17 PM
We plan to file Lunsumio subcut in the second half of 2024 with global regulators. (I haven't really looked into this but I am assuming Halo is not involved and I wonder if any other company is.)
It appears you are correct that it is not associated with HALO. The last Halozyme slide set shows only one other Roche indication in the pipeline and it is in ph1.
The more you know, the less you don't know.
Recent HALO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 08:13:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/11/2026 08:10:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:06:06 PM
- HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE • PR Newswire (US) • 05/11/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:04:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:03:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:02:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2026 11:01:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 08:16:24 PM
- Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets • PR Newswire (US) • 05/07/2026 01:00:00 PM
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology • PR Newswire (US) • 05/06/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 09:05:10 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:45:44 PM
- Halozyme to Report First Quarter 2026 Financial and Operating Results • PR Newswire (US) • 04/30/2026 08:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 02:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 12:12:51 PM
- Halozyme Appoints Darren Snellgrove as Chief Financial Officer • PR Newswire (US) • 04/30/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:06:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 09:13:42 PM
- Halozyme signs licensing deal with Vertex for drug delivery technology • IH Market News • 04/07/2026 02:11:29 PM
- Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology • PR Newswire (US) • 04/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:29:18 PM
